A Study to Learn About the Long-Term Health of Adult Participants From a Previous Study of a New Melanoma Treatment
Enrolling by invitation · Phase 2 · NCT06848088
Conditions: Melanoma
At a glance
- Research payments reported, 2025
- $226,775
- U.S. investigators named
- 6
- Sites paid
- 6
- Planned or actual enrollment
- 48
About the trial
- Sponsor
- Regeneron Pharmaceuticals
- Tested
- Fianlimab+cemiplimab (drug)
- Dates
- Started 2025-04-14; completion 2029-10-10
- Results posted
- Not yet
This study is researching the long-term effects of a combination of experimental drugs called fianlimab and cemiplimab. The study is being conducted in patients with advanced skin cancer (melanoma) who had previously been treated with fianlimab and cemiplimab in the study called R3767-ONC-1613 (NCT03005782). The aim of the current study is to see how safe and effective the study drugs are in a long-term follow-up. No study drug will be given during this study. Cancer status will be monitored, in addition to routine care. The study is also collecting information about general health status, and other treatments that may have been received since participation in study R3767-ONC-1613 (NCT030…
From ClinicalTrials.gov, last updated 2026-07-13. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Regeneron Pharmaceuticals, Inc. reported $226,775 in research payments for this study in 2025 (29 payments).
Products named: Libtayo
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Omid Hamid, M.D. Hematology & Oncology · Santa Monica, CA
- Kevin B. Kim, M.D. Medical Oncology · San Francisco, CA
- Nehal J. Lakhani, M.D. Hematology & Oncology · Grand Rapids, MI
- Amy M. Weise, D.O. Medical Oncology · Detroit, MI
- Meredith A. Mckean, M.D. Hematology & Oncology · Nashville, TN
- Kyriakos P. Papadopoulos, M.D. Hematology & Oncology · San Antonio, TX
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Cedars Sinai Medical Care Foundation $90,444
- South Texas Accelerated Research Therapeutics LLC $58,319
- Sarah Cannon Research Institute LLC $39,198
- Henry Ford Health Hospital, MI $35,268
- Start Midwest LLC $1,805
- California PAcific Medical Center- Van Ness Campus, CA $1,742
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.